Download DNB 2019 Dec 2019 Dec RHEUMATOLOGY PAPER II Question Paper

FirstRanker.com

DECEMBER 2019

RHEUMATOLOGY

--- Content provided by‌ FirstRanker.com ---

PAPER-II

Time: 3 hours RHM/D/19/43/1 Max. Marks:100

Important Instructions:

• Attempt all questions in order.
• Each question carries 10 marks.

--- Content provided by‌ FirstRanker.com ---

• Read the question carefully and answer to the point neatly and legibly.
• Do not leave any blank pages between two answers.
• Indicate the question number correctly for the answer in the margin space.
• Answer all the parts of a single question together.
• Start the answer to a question on a fresh page or leave adequate space between two answers.

--- Content provided by‌ FirstRanker.com ---

• Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a) Discuss EULAR recommendation 2019 for the management of Sjogren’s syndrome. 7+3
   b) Name some tests done for testing dry eyes.
2. a) Discuss rheumatological manifestations of tuberculosis. 8+2
   

   --- Content provided by‌ FirstRanker.com ---

   b) What is Poncet's disease?
3. a) Describe the evolution of psoriatic arthritis criteria. 5+5
   b) Name the disease activity indices in psoriatic arthritis.
4. a) What is the technique, indication, precaution taken for doing muscle biopsy? 5+5
   b) Compare and contrast the immunohistochemistry, histopathological findings in dermatomyositis and polymyositis.

--- Content provided by FirstRanker.com ---

5. a) How do you approach a patient with pulmonary renal syndrome? 2+(4+4)
   b) Name the causes, clinical presentation and management of pulmonary renal syndrome.
6. Assessment of disease activity in primary large vessel vasculitis and management of Giant cell arteries. 5+5
7. Name the various chloroquine and hydroxychloroquine related ocular toxicities and methods of early detection of the same. 5+5
8. Utility of PET-CT in rheumatology practice. 10

--- Content provided by​ FirstRanker.com ---

9. Classify lupus nephritis. Discuss management of lupus nephritis. 2+8
10. Clinical manifestations of antiphospholipid syndrome and management. 5+5

POSSESSION/USE OF CELL PHONES OR ANY GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.